Haemonetics Corp. Company Profile (NYSE:HAE)

Analyst Ratings

Consensus Ratings for Haemonetics Corp. (NYSE:HAE) (?)
Ratings Breakdown: 1 Sell Rating(s), 5 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $32.25 (7.32% upside)

Analysts' Ratings History for Haemonetics Corp. (NYSE:HAE)
Show:
DateFirmActionRatingPrice TargetActions
5/16/2016Goldman Sachs Group Inc.UpgradeSell -> Neutral$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2016BTIG ResearchReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Morgan StanleyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Benchmark Co.Lower Price TargetHold$35.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Barrington ResearchLower Price TargetOutperform$40.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Jefferies GroupBoost Price TargetBuy$38.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016William BlairReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/23/2015Raymond James Financial Inc.DowngradeMarket Perform -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Haemonetics Corp. (NYSE:HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016Q117$0.28$205.41 millionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/27/2015Q415$0.52$0.47$239.20 million$226.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/29/2015Q315$0.15$0.53$235.45 million$231.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q215$0.46$0.47$229.90 million$227.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q115$0.36$0.38$215.85 million$224.49 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2012$0.71$0.55ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2012$0.83$0.80ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2012$0.80$0.86ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2011$0.77$0.72ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2011$0.77$0.65ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2011$0.83$0.85ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2011$0.82$0.89ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Haemonetics Corp. (NYSE:HAE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.43$0.49$0.46
Q2 20163$0.25$0.33$0.29
Q3 20164$0.40$0.46$0.44
Q4 20164$0.48$0.57$0.54
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.33$0.40$0.37
Q4 20173$0.37$0.43$0.40
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics Corp. (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Haemonetics Corp. (NYSE:HAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Haemonetics Corp. (NYSE:HAE)
DateHeadline
07/27/16 04:37 PMHAEMONETICS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
07/27/16 04:08 PMHAEMONETICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
07/26/16 08:22 AMHaemonetics Corp. :HAE-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 -
07/25/16 04:25 PMNew Research Report on Hemostasis Testing Systems Market, 2016-2026
07/18/16 04:19 PMHaemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016 - [PR Newswire] - BRAINTREE, Mass., July 18, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) today announced that the Company will publish fiscal year 2017 first quarter financial results at 6:00am Eastern Time ...
07/12/16 08:45 AMGlobal Blood Collection and Processing Supplie Industry
07/07/16 04:26 PMHemostasis Testing Systems Market size in terms of volume and value 2016-2026
07/05/16 11:11 AMHaemonetics Corp. – Value Analysis (NYSE:HAE) : July 5, 2016 -
07/01/16 07:16 AMHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : July 1, 2016 -
06/30/16 07:14 AMGlobal medical aspirator market forecast to 2021 detailed in new research report
06/28/16 04:20 PMMedical aspirator market growth and its future prospects in a new 2016 research report
06/23/16 03:35 PMContractual Waiver of Subrogation Applied to Owner’s Non-Work Property
06/21/16 07:15 AMHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : June 21, 2016 -
06/20/16 01:31 PMETF’s with exposure to Haemonetics Corp. : June 20, 2016 -
06/20/16 10:35 AMApheresis Market worth 2.5 Billion USD by 2020
06/14/16 04:14 PMHaemonetics : Sources Sought Notice - Maintenance Service Agreement for Haemonetics Units
06/07/16 12:04 PMHAEMONETICS CORP Financials -
06/06/16 04:15 PMHAEMONETICS CORP : Change in Directors or Principal Officers (form 8-K)
06/06/16 03:34 PMHAEMONETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers -
06/01/16 03:19 PMHAEMONETICS CORP Files SEC form 10-K, Annual Report -
06/01/16 07:00 AMInvetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s - [PR Newswire] - SAN DIEGO and BRAINTREE, Mass., June 1, 2016 /PRNewswire/ -- Invetech, a global leader in instrument development, custom automation and contract manufacturing, in collaboration with Haemonetics, a healthcare company dedicated to providing innovative blood management solutions, and Coramed Technologies, developer of CORA® technology for more personalized hemostasis therapy, today announced that the companies have been jointly named recipients of a 2016 Good Design Award® for product design in the medical and scientific category. The award recognizes the TEG® 6s hemostasis analyzer, a compact diagnostic instrument that provides clinicians with rapid, comprehensive and accurate identification of a patient's hemostasis condition in a laboratory or point-of-care setting. "As a tool that helps make better treatment decisions that lead to reduced risks, complications and costs, the TEG 6s system has been very well received by clinicians and laboratories in the U.S. and around the world," said Krista Thompson, Vice President of Hemostasis Management at Haemonetics.
05/26/16 04:53 PMOracle Corporation (NYSE:ORCL) Updated Price Targets - 02/22/2016 - V.F. Corporation had its "outperform" rating reiterated by analysts at Telsey Advisory Group. They now have a Dollars 70 price target on the stock. 10/06/2015 - Haemonetics Corporation had its "buy" rating reiterated by analysts at Jefferies.
05/26/16 07:57 AMQ1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million,compared to prior year Q1 period - [at noodls] - In the first quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 69.94 million (prior year period: EUR 45.16 million), an operating result (EBIT) of EUR 3.47 million ...
05/26/16 07:17 AMHaemonetics to Present at Jefferies 2016 Healthcare Conference - [at noodls] - BRAINTREE, Mass., May 26, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that Gerry Gould, Vice President - Investor Relations, will present at the Jefferies 2016 Healthcare Conference ...
05/26/16 05:47 AM2015: Preliminary IFRS results - [at noodls] - In the financial year 2015 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 229.7 million (prior year: EUR 202.7 million) and an operating result (EBIT) of EUR 8.2 million (prior ...
05/26/16 04:37 AMQ1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period - [at noodls] - In the first quarter 2016 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS Group sales of EUR 69.94 million (prior year period: EUR 45.16 million), an operating result (EBIT) of EUR 3.47 million ...
05/17/16 04:35 PMTech firms name new CEOs - Haemonetics Corp., a Braintree-based manufacturer of devices that collect and process blood for health care customers, named former McKinsey & Co. senior partner Christopher Simon as its new president and CEO May 9. Simon, an Army veteran, had been leading ...
05/16/16 09:34 PMHaemonetics Corporation (NYSE:HAE) Receives Neutral Rating From Goldman Sachs Analysts - On Monday Goldman Sachs upgraded its price target on shares of Haemonetics Corporation (NYSE:HAE) giving the company a "Neutral" rating. The healthcare company recently issued its fiscal 2017 forecast that calls for adjusted earnings of $1.40-$1.50 per ...
05/16/16 05:48 AMHaemonetics upgraded by Goldman -
05/11/16 10:20 PMBenchmark Co. Trims Haemonetics Co. (HAE) Target Price to $28.00 - Washington News Wire - Washington News WireBenchmark Co. Trims Haemonetics Co. (HAE) Target Price to $28.00Washington News WireHaemonetics logo Haemonetics Co. (NYSE:HAE) had its price target cut by analysts at Benchmark Co. from $35.00 to $28.00 in a report released on Wednesday, ARN reports. The brokerage currently has a “hold” rating on the stock. Benchmark Co.'s price ...Haemonetics Co. (NYSE:HAE) Given Consensus Recommendation of "Hold" by AnalystsWeb Breaking Newsall 9 news articles »
05/11/16 03:18 AMLayoffs ahead as Haemonetics restructures, names new CEO - Haemonetics also issued its sales and earnings guidance for the fiscal 2017 year ending next April that missed the consensus expectation on Wall Street. Simon, who leads the global medical products practice at McKinsey & Co., also led the management ...
05/10/16 06:08 AMBRIEF-Haemonetics plans repositioning organization, reduce number of employees - * On may 6, 2016, co committed to a plan for repositioning organization and cost structure; this involves reduction in number of employees
05/10/16 05:02 AMHAEMONETICS CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors or Princi -
05/09/16 10:05 PMShares now down at $27.27 Haemonetics Corporation Announces… - Haemonetics Corporation Common (NYSE:HAE): Haemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer. The company is so far trading down by -1.91% since yesterday’s close of $27.8. The stock is trading at $27.27 a tad ...
05/09/16 10:05 PMHaemonetics (HAE) Names New CEO; Guides FY17 Below Expectations - Haemonetics Corporation (NYSE: HAE) announced the appointment of Christopher Simon as President and Chief Executive Officer of the Company. Chris, who currently serves as a Senior Partner of McKinsey & Company where he leads the Global Medical Products ...
05/09/16 10:05 PMBRIEF-Haemonetics Corp announces Christopher Simon as CEO - Haemonetics corporation announces Christopher Simon as president and chief executive officer * Chris currently serves as a senior partner of Mckinsey & Company Source text for Eikon: Further company coverage: Thomson Reuters is the world's largest ...
05/09/16 04:58 PMWith Shares Trading down at $27.27 Haemonetics Provides Fiscal 2017… - Haemonetics Corporation Common (NYSE:HAE): Haemonetics Provides Fiscal 2017 Guidance. The company is so far trading down by -1.91 percent from yesterday’s close. Shares last traded at $27.27 which is a tad under the 50 day moving average which is $33.11 ...
05/09/16 04:28 PMHaemonetics Corporation Announces Christopher Simon as President and Chief Executive Officer - [at noodls] - BRAINTREE, Mass., May 9, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) a global healthcare company dedicated to providing innovative solutions to our customers, today, announced the appointment ...
05/09/16 04:28 PMHaemonetics Provides Fiscal 2017 Guidance - [at noodls] - BRAINTREE, Mass., May 9, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) provided guidance for its fiscal year ending April 1, 2017. The Company follows a fiscal year reporting convention, ending ...
05/09/16 02:25 PMETF’s with exposure to Haemonetics Corp. : May 9, 2016 -
05/05/16 11:16 AMHaemonetics Corp. :HAE-US: Earnings Analysis: Q4, 2016 By the Numbers -
05/04/16 03:20 AMJefferies Thinks Haemonetics Corp.'s Stock is Going to Recover - Markets.co - Jefferies Thinks Haemonetics Corp.'s Stock is Going to RecoverMarkets.coAccording to The Fly, jefferies analyst Anthony Petrone reiterated a Buy rating on Haemonetics Corp. (NYSE: HAE) yesterday and set a price target of $32. The company's shares closed yesterday at $27.65, close to its 52-week low of $27.52. Petrone noted ...
05/03/16 06:03 AMHaemonetics (HAE) Lags Q4 Earnings, Sales; Margins Drop -
05/02/16 05:24 PMShares Trading down at $32.43 (HAE) Haemonetics Reports 4th Quarter Fiscal… - Haemonetics Corporation Common (NYSE:HAE): Haemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth o. The company ...
05/02/16 05:24 PMHaemonetics Corporation (HAE) Stock Tumbles on Bottom-Line Weakness - Haemonetics Corporation (NYSE:HAE) stock declined over 14% today, after the company disclosed fourth quarter of fiscal 2016 (4QFY16) financial results in the morning. It posted a substantial miss on the bottom-line, despite the top-line being almost in ...
05/02/16 04:45 PMWhy Baidu, Pandora Media, and Haemonetics Slumped Today -
05/02/16 01:09 PMEdited Transcript of HAE earnings conference call or presentation 2-May-16 12:00pm GMT -
05/02/16 05:36 AMHAEMONETICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/02/16 05:31 AMHaemonetics reports 4Q loss -
05/02/16 05:20 AMHaemonetics Reports 4th Quarter Fiscal 2016 Revenue of $243 Million, Constant Currency Revenue Growth of 10% and 7% As Reported; Fiscal 2016 Revenue of $910 Million, Constant Currency Revenue Growth of 3% and Flat As Reported - [at noodls] - BRAINTREE, Mass., May 2, 2016 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) reported fourth quarter fiscal 2016 revenue of $243.2 million, up 7%. Revenue was up 10% over the fourth quarter of fiscal ...

Social

About Haemonetics Corp.

Haemonetics Corp. logoHaemonetics Corporation is a healthcare company, which provides blood management solutions to its customers. The Company's portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood supply chain. It serves three customer segments: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Its multiple product lines under four global product categories include Plasma, Blood Center, Hospital and Software Solutions. Its Plasma includes plasma collection devices and disposables. Its Blood Center includes blood collection and processing devices and disposables. Its Hospital includes surgical blood salvage and blood demand diagnostic devices and disposables. Its Software Solutions includes information technology platforms and consulting services provided to all three markets. It operates in North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific and Japan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NYSE
  • Symbol: HAE
  • CUSIP: 40502410
Key Metrics:
  • Previous Close: $30.05
  • 50 Day Moving Average: $29.59
  • 200 Day Moving Average: $31.07
  • P/E Ratio: N/A
  • P/E Growth: 4.08
  • Market Cap: $1.53B
  • Beta: 0.77
  • Current Year EPS Consensus Estimate: $1.45 EPS
  • Next Year EPS Consensus Estimate: $1.62 EPS
Additional Links:
Haemonetics Corp. (NYSE:HAE) Chart for Thursday, July, 28, 2016